Emisphere’s Proprietary Eligen Technology Supports Novo Nordisk’s Oral Semaglutide

World News: . []

ROSELAND NJ Aug 28 2018 GLOBE NEWSWIRE -- On LINK  20 2018 Novo Nordisk AS Novo Nordisk LINK  the headline results from LINK  5 a phase 3a trial with oral semaglutide in adults with type 2 diabetes and LINK  renal impairmen t. A co...

More news and information about Emisphere Technologies, Inc.

Published By:

Globe Newswire: 21:05 GMT Tuesday 28th August 2018

Published: .

Search for other references to "emisphere" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us